Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Disappointing Pricing for China Nuokang’s Nasdaq IPO

publication date: Dec 10, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
China Nuokang Bio-Pharmaceutical priced its IPO at $9, which was slightly below the expected range of $10-$12. When the shares began trading today, they fell further, dropping 56 cents to $8.44, a loss of about 6%. The company receives 94% of its revenues from a single product, the hemocoagulant Baqueting, which is derived from the venom of the pit viper. More details...

Stock Symbol: (NSDQ: NKBP)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...